Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | CCR5 | P51681 | 14/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17366552 | 0.95 | DRD2 (0.64) | DRD2SIGMAR1DRD3CCR5 | |
| SCHEMBL21654485 | 0.95 | DRD2 (0.64) | DRD2SIGMAR1DRD3CCR5 | |
| SCHEMBL20691262 | 0.90 | DRD2 (0.60) | DRD2SIGMAR1DRD3CCR5 | |
| SCHEMBL24224379 | 0.86 | DRD2 (0.53) | DRD2SIGMAR1DRD3CCR5 | |
| SCHEMBL17364176 | 0.84 | DRD2 (0.52) | DRD2SIGMAR1DRD3CCR5CCR2 | |
| SCHEMBL29358988 | 0.84 | DRD2 (0.52) | DRD2SIGMAR1DRD3CCR5CCR2 | |
| Pridopidine SCHEMBL166748 | 0.83 | DRD2 (1.00) | DRD2SIGMAR1DRD3 | |
| Pridopidine SCHEMBL29664816 | 0.83 | DRD2 (1.00) | DRD2SIGMAR1DRD3 | |
| Pridopidine SCHEMBL15007479 | 0.82 | DRD2 (0.97) | DRD2SIGMAR1DRD3 | |
| Pridopidine SCHEMBL2370301 | 0.82 | DRD2 (0.97) | DRD2SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2024-07-16 | — | — | US | disclosed |
| US-20230355595-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | US | disclosed |
| US-20230330073-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| US-20230190724-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-06-22 | — | — | US | disclosed |
| US-20230181548-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-06-15 | — | — | US | disclosed |
| US-20230165849-A2 | USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-06-01 | — | — | US | disclosed |
| US-20230165849-A2 | USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-06-01 | — | — | US | disclosed |
| EP-4049998-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd. (IL) | 2022-08-31 | — | — | EP | disclosed |
| EP-3160470-B1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd (IL) | 2022-08-03 | — | — | EP | disclosed |
| US-20220202798-A1 | USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2022-06-30 | — | — | US | disclosed |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-01-31 | — | — | US | disclosed |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2018-11-20 | — | — | US | disclosed |
| EP-3160470-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Teva Pharmaceutical Industries Ltd (IL) | 2017-05-03 | — | — | EP | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2017015609-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016003919-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016003919-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-07 | — | — | WO | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355595-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | HTT, PARK7, DRD1 | DRD2 4/4885SIGMAR1 377/4885DRD3 25/4885 |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | PDE6D, QDPR, PDE4D | DRD2 15/4885SIGMAR1 826/4885DRD3 55/4885 |
| US-20230181548-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PDE12, PDE3A, PDE3B | DRD2 16/4885SIGMAR1 341/4885DRD3 44/4885 |
| US-20220202798-A1 | USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME | CYFIP1, CYFIP2, LPXN | DRD2 4/4885SIGMAR1 1180/4885DRD3 29/4885 |
| US-20230190724-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE | SMN1; SMN2, LPXN, SNCA | DRD2 49/4885SIGMAR1 817/4885DRD3 209/4885 |
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | SLC6A3, QDPR, PARK7 | DRD2 5/4885SIGMAR1 1492/4885DRD3 29/4885 |
| US-20230165849-A2 | USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME | QDPR, PRPH, PDE6A | DRD2 13/4885SIGMAR1 3240/4885DRD3 41/4885 |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 12/4885DRD3 5/4885 |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 14/4885DRD3 5/4885 |
| US-20230330073-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | HTT, HYPK, PARK7 | DRD2 4/4885SIGMAR1 268/4885DRD3 33/4885 |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 14/4885DRD3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.